Cargando…

Neural precursor cells induce cell death of high-grade astrocytomas via stimulation of TRPV1

Primary astrocytomas of World Health Organization grade 3 and grade 4 (HG-astrocytomas) are preponderant among adults and are almost invariably fatal despite multimodal therapy. Here, we show that the juvenile brain has an endogenous defense mechanism against HG-astrocytomas. Neural precursor cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Stock, Kristin, Kumar, Jitender, Synowitz, Michael, Petrosino, Stefania, Imperatore, Roberta, Smith, Ewan St. J., Wend, Peter, Purfürst, Bettina, Nuber, Ulrike A., Gurok, Ulf, Matyash, Vitali, Wälzlein, Joo-Hee, Chirasani, Sridhar R., Dittmar, Gunnar, Cravatt, Benjamin F., Momma, Stefan, Lewin, Gary R., Ligresti, Alessia, De Petrocellis, Luciano, Cristino, Luigia, Di Marzo, Vincenzo, Kettenmann, Helmut, Glass, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480991/
https://www.ncbi.nlm.nih.gov/pubmed/22820645
http://dx.doi.org/10.1038/nm.2827
Descripción
Sumario:Primary astrocytomas of World Health Organization grade 3 and grade 4 (HG-astrocytomas) are preponderant among adults and are almost invariably fatal despite multimodal therapy. Here, we show that the juvenile brain has an endogenous defense mechanism against HG-astrocytomas. Neural precursor cells (NPCs) migrate to HG-astrocytomas, reduce glioma expansion and prolong survival by releasing a group of fatty acid ethanolamides that have agonistic activity on the vanilloid receptor (transient receptor potential vanilloid subfamily member-1; TRPV1). TRPV1 expression is higher in HG-astrocytomas than in tumor-free brain and TRPV1 stimulation triggers tumor cell death via the activating transcription factor-3 (ATF3) controlled branch of the ER stress pathway. The anti-tumorigenic response of NPCs is lost with aging. NPC-mediated tumor suppression can be mimicked in the adult brain by systemic administration of the synthetic vanilloid Arvanil, suggesting that TRPV1 agonists hold potential as new HG-astrocytoma therapeutics.